Lilly's Alimta combination cancer therapy fails trial
Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients.
Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.
- Scots vote on independence, United Kingdom's fate on knife-edge |
- Australian PM says police raids follow IS linked beheading plot |
- Islamic State shows captive British journalist in new video
- Chinese hacked U.S. military contractors: Senate panel
- China not warlike, says Xi, as border standoff dominates India trip